Publications by authors named "Marcellusi A"
Introduction: Asthma is a prevalent chronic respiratory condition that significantly impacts public health, with severe asthma subtypes, such as severe eosinophilic asthma, imposing substantial socioeconomic burdens.
Methods: Real-world data from the Italian Health Information System were analyzed to evaluate the economic consequences of asthma in Italy. An in-depth comparative analysis was conducted to investigate the economic implications of various asthma subtypes, focusing on severe eosinophilic asthma.
Burden of Disease of Breast Cancer in Italy: A Real-World Data Analysis.
Pharmacoecon Open
November 2024
Background: Breast cancer (BC) constitutes a significant public health challenge in Italy, with a considerable impact on healthcare resources and societal costs. Despite advancements in diagnostics and therapies, the economic burden of BC remains substantial, necessitating a comprehensive evaluation to inform healthcare policy and resource allocation. The aim of this study is to estimate both direct health costs and social security costs related to BC.
View Article and Find Full Text PDFBackground: Chronic kidney disease (CKD)-associated pruritus is a condition that strongly impacts CKD patients and is associated with increased morbidity/mortality, and worse health-related quality of life (HRQoL). Difelikefalin is currently the only drug approved in Europe specifically for treating moderate to severe CKD-associated pruritus in patients undergoing hemodialysis. The KALM-1 and KALM-2 trials showed better efficacy of difelikefalin vs placebo and best supportive care.
View Article and Find Full Text PDFUnlabelled: BACKGROUND AND OBJECTIVE: Untreated spinal muscular atrophy (SMA) is the leading genetic cause of death in children younger than 2 years of age. Early detection through newborn screening allows for presymptomatic diagnosis and treatment of SMA. With effective treatments available and reimbursed by the National Health Service, many regions in Italy are implementing newborn screening for SMA.
View Article and Find Full Text PDFArticle Synopsis
- - The study analyzes the cost-effectiveness of pembrolizumab combined with chemotherapy for treating metastatic non-small cell lung cancer and as an adjuvant treatment for stage III melanoma in Italy, aiming to provide insights for better healthcare management.
- - A comprehensive cost-effectiveness model was constructed, evaluating the health outcomes and economic impacts (QALYs and DALYs) over a 40-year period from the perspective of the Italian National Health Service, including a significant number of patient cohorts.
- - Findings indicate substantial cost savings linked to the use of pembrolizumab over traditional treatments, with notable direct cost offsets associated with squamous and non-squamous NSCLC and melanoma treatments.
Introduction: This study aims to define the distribution of direct healthcare costs for people with diabetes treated in two healthcare regions in Italy, based on number of comorbidities and treatment regimen.
Methods: This was a retrospective analysis using data from two local health authority administrative databases (Campania and Umbria) in Italy for the years 2014-2018. Data on hospital care, pharmaceutical and specialist outpatient and laboratory assistance were collected.
Article Synopsis
- Gliomas are diverse tumors linked to significant health issues and healthcare costs, with poor survival rates for certain types like glioblastoma, often leading to less than a year of life after diagnosis.
- The review discusses glioma's classification, epidemiology, treatment options, and gives specific recommendations for managing different types, emphasizing maximum safe resection followed by standard therapies.
- Challenges persist in glioma treatment due to inadequate therapy post-surgery and disappointing results from newer immunotherapies, highlighting the need for better clinical practices and ongoing research for effective treatment strategies.
Background And Aims: Italy has the greatest burden of hepatitis C virus (HCV) infection in Western Europe. The screening strategy represents a crucial prevention tool to achieve HCV elimination in Italy. We evaluated the cost-consequences of different screening strategies for the diagnosis of HCV active infection in the birth cohort 1948-1968 to achieve the HCV elimination goal.
View Article and Find Full Text PDFArticle Synopsis
- Italy has the highest rates of hepatitis C virus (HCV) infection and liver cancer deaths in Europe, but new treatments have expanded access, with over 244,000 people treated.
- While HCV-related deaths are expected to drop by 75% by 2030, Italy is at risk of not eliminating HCV completely by that time.
- To improve HCV elimination efforts, recommendations include expanding screening to more populations, raising awareness, ensuring continued access to direct-acting antivirals, and customizing care for high-risk groups.
The prognostic impact of coronary artery disease (CAD) after transcatheter aortic valve implantation (TAVI) is controversial. The aim of this study is to investigate the impact of CAD and different revascularization strategies on clinical outcomes in patients who underwent TAVI with third generation devices. Patients enrolled in the national observational Observational Study of Effectiveness of SAVR-TAVI Procedures for Severe Aortic Stenosis Treatment II study were stratified according to the presence of CAD (CAD+, n = 1,130) versus no CAD (CAD-, n = 1,505), and compared using a propensity matched analysis.
View Article and Find Full Text PDFArticle Synopsis
- The study focused on the financial impact of transcatheter aortic valve implantation (TAVI) therapy due to a growing eligible patient population, comparing costs over two different time periods.
- A Markov model was used to analyze costs from two patient groups: 1,898 with old-generation TAVI devices and 1,417 with newer devices, highlighting significant cost differences.
- Results showed new-generation TAVI led to 30% fewer rehospitalizations and a 20% decrease in 1-year mortality, resulting in total cost savings of €23.8 million, primarily driven by reduced rehospitalization costs.
Objectives: Italy was the first European country to introduce universal vaccination of adolescents, for both males and females, against Human Papilloma Virus (HPV) starting in 2017 with the NIP 2017-2019's release. However, vaccine coverage rates (VCRs) among adolescents have shown a precarious take-off since the NIP's release, and this situation worsened due to the impact of the COVID-19 pandemic in 2020. The aim of this work is to estimate the epidemiological and economic impact of drops in VCRs due to the pandemic on those generations that missed the vaccination appointment and to discuss alternative scenarios in light of the national data.
View Article and Find Full Text PDFBackground And Objective: HPV (human papillomavirus) is the virus most often responsible for sexually transmitted infections. The burden of HPV-related diseases on hospital resources represents a major public health problem. The objective of this study was to quantify the lifetime economic burden of HPV-related diseases based on hospital resources from the perspective of National Health Service (NHS) in England.
View Article and Find Full Text PDFBackground: Data reflecting the benefit of procedural improvements in real-world transcatheter aortic valve implantation (TAVI) practice are sparse.
Aims: To compare outcomes and trends of two TAVI eras from real Italian practice.
Methods: A total of 1811 and 2939 TAVI patients enrolled in the national, prospective OBSERVANT and OBSERVANT II studies in 2010-2012 and 2016-2018, respectively, were compared in a cohort study.
Background And Objective: During 2020, the only instruments for fighting against the pandemic peaks were lockdowns, physical distancing, closure of schools and non-essential businesses, and travel restrictions. The new vaccination strategy adopted in Italy in 2021 represented a new perspective for policymakers.
Objective: The aim of this study was to estimate the effects of the national immunisation strategy for coronavirus disease 2019 (COVID-19) in Italy on the national healthcare system.